Citi analyst Yigal Nochomovitz has maintained their bullish stance on ZBIO stock, giving a Buy rating on July 2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yigal Nochomovitz has given his Buy rating due to a combination of factors that suggest a promising future for Zenas BioPharma, Inc. The company’s lead product, obexelimab, shows a unique advantage over existing therapies, particularly in its potential safety and efficacy benefits compared to CD20-depleting monoclonal antibodies. This differentiation is expected to be particularly appealing for patients with reduced mobility, as it allows for at-home administration.
Furthermore, the anticipated pipeline developments, including the Phase 2 and Phase 3 trial readouts for multiple sclerosis and IgG4-related disease by the end of 2025, are expected to significantly enhance the company’s stock value. The company’s financial runway is secure until the fourth quarter of 2026, and there is potential for business development activities in the near future. These elements contribute to a favorable risk/reward profile, with an expected share price return of 157.4%, making Zenas BioPharma an attractive investment opportunity.
According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 4.5% and a 41.02% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Arcturus Therapeutics, and Krystal Biotech.
In another report released on July 2, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $31.00 price target.